Gabapentin Capsule
Product Images NDC 71335-2700

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Gabapentin Fig1)

A formula table depicting the Creatinine Clearance (CLCr) calculation. It shows the equation involving age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 specifically for female patients. This mathematical formula assists in estimating kidney function.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing mean pain scores over 8 weeks for Gabapentin at 3600 mg/day versus placebo. The x-axis represents weeks, from baseline to 8, with labeled periods for a 4-week dose titration and a 4-week fixed dose. The y-axis shows mean pain scores ranging from 0 to 9. Gabapentin shows a decreasing pain score trend, while placebo scores remain relatively constant.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain score over a 7-week period, comparing placebo with Gabapentin at daily doses of 1800 mg and 2400 mg. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Mean pain scores decrease over time for gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups across two studies. Study 1 shows responder rates of 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for gabapentin groups versus placebo.*

FDA Label Image

Fig-5 (Gabapentin Fig5)

A scatter plot chart illustrating the percentage difference against daily dose in mg for Gabapentin; it displays data points for three distinct studies (Study a, Study b, Study c) with daily doses ranging from 600 mg to 1800 mg on the x-axis and percentage difference from 2% to 22% on the y-axis.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Label (Lbl713352700)

Label for Gabapentin Capsules USP 400 mg, with NDC 71335-2700. The label indicates a package of 20 capsules, repackaged by Bryant Ranch Prepack, Inc., and manufactured by Aurobindo Pharma Limited. Storage instructions and warnings about child-resistant containers are included, as well as QR codes for the package insert and prescribing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.